New FDA-approved clot removal devices show promise for treating stroke patients
Dr. David Fiorella with patient Shelley Broven.
Specialists at Stony Brook Medicine's Cerebrovascular and Stroke Center (CVC) are treating patients with a new generation of blood clot removal devices that show promise in successfully revascularizing stroke patients, including those with large vessel blockages. The Solitaire Flow Restoration Device and the Trevo device, approved by Food and Drug Administration (FDA) in 2012 to treat stroke caused by the sudden obstruction of a brain blood vessel (acute ischemic stroke) showed improved results over a previous standard and first generation clot-removal device in clinical trials.
"We have had excellent outcomes using these new devices," said David Fiorella, M.D., Ph.D., a Professor of Clinical Neurological Surgery and Radiology at Stony Brook University School of Medicine and Co-Director of the CVC. "In acute ischemic stroke, 'time is brain,' and in some cases just minutes matter. Therefore, restoring blood flow in an effective and timely manner is critical to the survival and recovery of stroke patients. These new devices enable us to quickly restore blood flow and retrieve the clot in most patients," said Dr. Fiorella, who has performed some 30 procedures on stroke patients using the new devices.
"These blot clot removal devices are an important new component of our armamentarium against stroke" said Henry Woo, MD, Professor of Neurological Surgery and Radiology and Co-Director of the CVC, who has also used both devices in patient procedures. "Our center provides endovascular treatment for acute stroke 24/7, and by having the latest technologies to remove brain blood clots, and the expertise to perform endovascular procedures, our Center remains on the cutting-edge against this life-threatening condition."
According to the American Stroke Association, stroke remains the fourth leading cause of death and leading cause of adult disability in the United States. On average a stroke occurs every 40 seconds in the country, and someone dies from a stroke every four minutes. These statistics speak to the need to develop more effective drugs, devices, and procedures to treat stroke.
This video is not supported by your browser at this time.Recent results of clinical trials reported in The New England Journal of Medicine (February 2013) about the use of first generation of blood clot removal devices in the endovascular treatment of acute ischemic stroke revealed that endovascular treatment does not result in better patient outcomes compared to standard drug treatments. Dr. Fiorella contends that while these trial results are important in the search for the best treatment protocols for acute ischemic stroke, the new devices and techniques are markedly better than those used to treat the majority of patients in these trials and may yet prove to be the most effective approach in select patients. Further research trials are being conducted at Stony Brook to investigate the efficacy of these newer, better devices in acute ischemic stroke.
The new devices that Stony Brook cerebrovascular specialists use to perform revascularization are expandable wire-mesh systems that collapse and are delivered into the brain blood vessels through small flexible tubes (microcatheters) which are guided from the groin to the brain. The devices open at the site of the clot, displacing the occlusion and immediately restoring blood flow to the brain. When the devices are withdrawn from the blood vessel, they take the clot with them, allowing the clot to be removed from the blood vessel.
Dr. Fiorella said that while intravenous clot-busting drugs remain a standard part of stroke therapy, endovascular therapies using the new devices are particularly beneficial when treating certain stroke patients.
"In many of the more severe stroke cases where the main arteries of the brain are blocked, intravenous medications are predictably ineffective, failing to open the occluded artery in 70 to 90 percent of the cases. Also, many patients are not eligible for intravenous clot busting medication because of their time of presentation, existing medical conditions, recent surgery, or the medications they take, such as blood thinners," he explained. "In these cases where intravenous medications are ineffective or contraindicated, endovascular treatments using these new devices offer patients the most promise."
"I feel extremely good and am able to do the things I did before my stroke, and that includes taking care of my grandchildren and running road races," said Michael Jezewski, 66, a retiree from Centereach, N.Y., who ran a five kilometer race just two months after his May 2012 stroke. "I believe that Dr. Fiorella's procedure did save my life and contributed greatly to my quick recovery."
Jezewski did not have a history of stroke and collapsed while at doctor's appointment. He was rushed to Stony Brook where Dr. Fiorella performed endovascular treatment with one of the new devices within two hours of Jezewski's sudden collapse. Jezewski's symptoms started with fatigue and no feeling on the right side of his body, and then quickly progressed to paralysis and the inability to speak. Upon awaking from the clot removal procedure, the majority of his symptoms had completely resolved.
When Shelley Broven, 66, of Setauket, N.Y., began to feel dizzy and had a hard time speaking during her husband's 70th birthday party in November 2012, friends called an ambulance from the restaurant. She was rushed to Stony Brook where Dr. Fiorella performed endovascular treatment with a new generation device.
"I don't recall much of what happened after that incident, but within a week I was out of the hospital, beginning rehabilitation, and feeling pretty good," said Broven. "Each week I have more energy and can express myself more clearly," added Broven, whose stroke resulted from a nearly completely blocked carotid artery which sent a blood clot into her brain blood vessels.
About the New Devices
In two separate multicenter clinical trials reported in The Lancet the new devices were compared to a standard first generation clot removal device called the Merci Retriever.
In one published report, the Solitaire device opened blocked arteries in approximately 70 percent of the patients, compared to only 30 percent treated with the previous device. When other therapies were used with Solitaire, the success rate improved to 80 percent. After three months, 58 percent of the patients with the Solitaire device had a good neurological outcome in comparison to 33 percent of those treated with the standard device. In addition, the mortality rates were less than half in those treated with the newer generation device.
Another published report compared the Trevo device with the Merci Retriever. In this trial, the new Trevo device was superior to the older device, with an 86 percent success rate in opening the blocked brain blood vessel. When other therapies were added, the Trevo device success rate was more than 90 percent.
Provided by Stony Brook University
- New device performs better than old for removing blood clots Feb 03, 2012 | not rated yet | 0
- New device to remove stroke-causing blood clots proves better than standard tool Aug 26, 2012 | not rated yet | 0
- The Medical Minute: Solitaire for stroke -- It's not a game May 22, 2012 | not rated yet | 0
- Adding endovascular therapy to tPA didn't improve recovery after stroke Feb 08, 2013 | not rated yet | 0
- 'Clot-buster' drug may still be best stroke treatment Feb 07, 2013 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
understanding the dipole model for Rayleigh scattering
2 hours ago Hello. I am currently studying scattering theory in detail for my BSc thesis, and I'm starting with Rayleigh scattering. I'm following Scattering...
question on coriolis effect with drag force
8 hours ago I really need help with this question. A small floating object initially moves with velocity v on the surface of a liquid at latitude λ. The...
Question of reflection and transmission of TEM wave in normal incidenc
13 hours ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
14 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
15 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
21 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
- More from Physics Forums - Classical Physics
More news stories
(HealthDay)—In patients who have previously been considered difficult to image, dual-source cardiac (DSC) computed tomography (CT) can identify clinically significant coronary artery disease, according ...
Cardiology 12 hours ago | not rated yet | 0
UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden ...
Cardiology 14 hours ago | not rated yet | 0
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
Cardiology 19 hours ago | not rated yet | 0
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology May 22, 2013 | not rated yet | 0
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology May 22, 2013 | not rated yet | 0
Artemio Martinez balanced his corpulent frame on a stool in a Mexico City street taco stand, downing a sweet soda and eating a final pork-filled corn tortilla.
17 minutes ago | not rated yet | 0
The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.
3 minutes ago | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
12 hours ago | 4.8 / 5 (6) | 0 |
The British Menopause Society and Women's Health Concern have today released updated guidelines on Hormone Replacement Therapy (HRT) to provide clarity around the role of HRT, the benefits and the risks. The new guidelines ...
1 hour ago | not rated yet | 0
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
18 hours ago | 4.5 / 5 (10) | 1 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
16 hours ago | 5 / 5 (1) | 2 |